2m 2m 2m 2m 2m 2m 2m
NURIX THERAPEUTC-RG (NRIX)
NASDAQ
$18.31-$0.34 (-1.82%)
Price as of Jun 23, 2026 6:25 PM EDT- $1.9BMarket Cap
- 55.68%1-Year Change
- BiotechnologyIndustry
NURIX THERAPEUTC-RG (NRIX)
$18.31-$0.34 (-1.82%)
Annual
Quarterly
11/30/2025 | 11/30/2024 | 11/30/2023 | 11/30/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 54.0M -1.04% | 54.5M -29.15% | 77.0M +99.31% | 38.6M +29.84% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 54.0M -1.04% | 54.5M -29.15% | 77.0M +99.31% | 38.6M +29.84% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -316.9M +42.99% | -221.6M +17.17% | -189.1M +2.52% | -184.5M +58.46% | |
Depreciation and Amortization Expense | 8.7M -6.20% | 9.3M +23.70% | 7.5M +40.83% | 5.3M +91.72% | |
Total Operating Expenses | 369.6M +38.15% | 267.6M +15.31% | 232.1M +4.29% | 222.5M +50.70% | |
Operating Profit | -285.7M +34.10% | -213.0M +37.38% | -155.1M -15.67% | -183.9M +55.97% | |
Interest Income | 22.0M +11.36% | 19.7M +77.49% | 11.1M +216.94% | 3.5M +326.12% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 22.0M +11.36% | 19.7M +77.49% | 11.1M +216.94% | 3.5M +326.12% | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Income before Taxes | -263.7M +36.42% | -193.3M +24.66% | -155.1M -14.03% | -180.4M +54.07% | |
Income Taxes | 760,000 +181.48% | 270,000 N/A | 0 N/A | 0 -100.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -264.5M +36.62% | -193.6M +34.47% | -143.9M -20.19% | -180.4M +53.90% | |
Net Income from Continuing Operations Applicable to Common | -263.7M +36.42% | -193.3M +34.28% | -143.9M -20.19% | -180.4M +54.07% | |
Basic EPS and Net Income | -3.05 +5.90% | -2.88 +8.68% | -2.65 -28.57% | -3.71 +35.90% | |
Diluted EPS and Net Income | -3.05 +5.90% | -2.88 +8.68% | -2.65 -28.57% | -3.71 +35.90% | |
Basic Weighted Average Shares | 86.7M +29.12% | 67.1M +23.52% | 54.3M +11.79% | 48.6M +13.32% | |
Diluted Weighted Average Shares | 86.7M +29.12% | 67.1M +23.52% | 54.3M +11.79% | 48.6M +13.32% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 247.0M +124.52% | 110.0M +101.36% | 54.6M -15.27% | 64.5M -19.91% | |
Short-Term Investments | N/A N/A | N/A N/A | 44.2M -81.94% | 244.7M +13.69% | |
Cash and Cash Equivalents and Short-Term Investments | 247.0M +124.52% | 110.0M +11.32% | 98.8M -68.04% | 309.1M +4.54% | |
Total Current Assets | 606.8M -2.03% | 619.4M +109.60% | 295.5M -7.21% | 318.4M +2.36% | |
Accumulated Depreciation | 37.8M +9.51% | 34.5M +31.44% | 26.2M +33.45% | 19.7M +32.20% | |
Property and Plant and Equipment and Net | 22.5M +26.65% | 17.8M +5.65% | 16.8M -2.07% | 17.2M +51.35% | |
Total Long-Term Assets | 7.3M +132.38% | 3.2M -17.37% | 3.8M -4.95% | 4.0M +41.97% | |
Total Assets | 688.1M +2.81% | 669.3M +88.23% | 355.6M -14.68% | 416.8M -12.59% | |
Income Taxes Payable | 1.1M -14.39% | 1.2M +4,023.33% | 30,000 -64.71% | 85,000 +13.33% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 86.5M -9.79% | 95.9M +10.23% | 87.0M +23.07% | 70.7M +6.64% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 62.9M +35.32% | 46.5M -31.77% | 68.1M +60.69% | 42.4M +4,889.18% | |
Total Liabilities | 149.4M +4.94% | 142.3M -8.22% | 155.1M +37.18% | 113.1M -15.92% | |
Retained Earnings | -1.0B +35.80% | -738.8M +35.50% | -545.2M +35.87% | -401.3M +81.65% | |
Total Stockholders Equity | 538.7M +2.23% | 527.0M +162.85% | 200.5M -33.98% | 303.7M -11.28% | |
Total Shares Outstanding | 101.8M +34.19% | 75.9M +55.73% | 48.7M +3.28% | 47.2M +5.62% | |
Cash Flow | |||||
Cash from Operating Activities | -249.5M +44.55% | -172.6M +112.11% | -81.4M -49.09% | -159.8M +89.42% | |
Capital Expenditures | 14.0M +51.00% | 9.3M +10.38% | 8.4M -31.39% | 12.2M +116.29% | |
Cash from Investing Activities | 147.9M +157.37% | -257.7M -477.32% | 68.3M +151.13% | 27.2M +125.12% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 238.6M -50.86% | 485.7M +14,996.89% | 3.2M -97.25% | 117.2M -23.84% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -529.21% +35.51% | -390.52% +93.89% | -201.41% -57.69% | -476.01% +20.13% | |
Return on Assets | -38.96% +3.15% | -37.77% +1.33% | -37.27% -7.67% | -40.37% +50.38% | |
Return on Equity | -49.63% -6.74% | -53.22% -6.80% | -57.10% +2.26% | -55.84% +50.70% | |
Revenue Growth | -1.04% -96.42% | -29.15% -129.35% | 99.31% +232.82% | 29.84% -55.43% | |
Current Ratio | 7.02 +8.60% | 6.46 +90.15% | 3.40 -24.60% | 4.51 -4.01% | |
Cash Ratio | 2.86 +148.89% | 1.15 +82.66% | 0.63 -31.16% | 0.91 -24.90% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow